Aardvark Therapeutics, Inc. (AARD)
$4.04-9.21%Close
SELLCRISIS · day 32
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $88M
- Beta
- 3.81
- P/E (TTM)
- -1.26
- Short % float
- 4.35%
- Days to cover
- 5.3
- SI change
- +11.6%
- 1W
- -19.84%
- 1M
- -27.21%
- vs SPY 1W
- -19.70%
- vs SPY 1M
- -29.71%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 18
- VALUE
- 11
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-42.9%
REV YoY-
ROE-71.5%
EPS YoY-
ROA-85.8%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-1.26
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B1.18
P/FCF-
EV/EBITDA-0.22
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.91
ALTMAN Z-
CURR RATIO12.63
ND/EBITDA-
BETA3.81
Company news
FAQ
- What is LOPJLB’s current signal on AARD?
- LOPJLB’s latest quantitative signal on Aardvark Therapeutics, Inc. Common Stock (AARD) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is AARD in?
- Aardvark Therapeutics, Inc. Common Stock (AARD) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Aardvark Therapeutics, Inc. Common Stock (AARD) do?
- Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It f…